tiprankstipranks
Traws Pharma (TRAW)
NASDAQ:TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

1,799 Followers
See the Price Targets and Ratings of:

TRAW Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Traws
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TRAW Stock 12 Month Forecast

There Are No Analyst Ratings for TRAW In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

TRAW Financial Forecast

TRAW Earnings Forecast

Next quarter’s earnings estimate for TRAW is -$0.25 with a range of -$0.25 to -$0.25. The previous quarter’s EPS was -$0.28. TRAW beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year TRAW has Outperformed its overall industry.
Next quarter’s earnings estimate for TRAW is -$0.25 with a range of -$0.25 to -$0.25. The previous quarter’s EPS was -$0.28. TRAW beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year TRAW has Outperformed its overall industry.

TRAW Sales Forecast

Next quarter’s sales forecast for TRAW is $60.00K with a range of $60.00K to $60.00K. The previous quarter’s sales results were ―. TRAW beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.62% of the time in the same period. In the last calendar year TRAW has Underperformed its overall industry.
Next quarter’s sales forecast for TRAW is $60.00K with a range of $60.00K to $60.00K. The previous quarter’s sales results were ―. TRAW beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.62% of the time in the same period. In the last calendar year TRAW has Underperformed its overall industry.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Noble Financial
$7
Buy
1405.38%
Upside
Reiterated
03/11/24
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (NASDAQ: ONTX) and Biogen (NASDAQ: BIIB)
H.C. Wainwright
$11
Buy
2265.59%
Upside
Reiterated
12/13/23
Onconova Therapeutics Buy Rating: Promising Potential of Narazaciclib as a Multi-Kinase Targeting Oncology Therapy

Best Analysts Covering Traws Pharma

Which Analyst Should I Follow If I Want to Buy TRAW and Sell After:
1 Month
Robert LeBoyerNoble Financial
Success Rate
4/16 ratings generated profit
25%
Average Return
-8.08%
reiterated a buy rating 3 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of -8.08% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Robert LeBoyerNoble Financial
Success Rate
4/16 ratings generated profit
25%
Average Return
-17.97%
reiterated a buy rating 3 months ago
Copying Robert LeBoyer's trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -17.97% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Robert LeBoyerNoble Financial
Success Rate
2/16 ratings generated profit
13%
Average Return
-42.77%
reiterated a buy rating 3 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -42.77% per trade.
2 Years
Robert LeBoyerNoble Financial
Success Rate
0/16 ratings generated profit
0%
Average Return
-59.13%
reiterated a buy rating 3 months ago
Copying Robert LeBoyer's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -59.13% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRAW Analyst Recommendation Trends

Rating
Aug 23
Oct 23
Nov 23
Dec 23
Mar 24
Strong Buy
9
7
5
4
3
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
7
5
4
3
In the current month, TRAW has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRAW average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

TRAW Stock Forecast FAQ

What is TRAW’s average 12-month price target, according to analysts?
Currently, no data Available
What is TRAW’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TRAW, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is TRAW a Buy, Sell or Hold?
      Currently, no data Available
      What is Traws Pharma’s price target?
      Currently, no data Available
      What do analysts say about Traws Pharma?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of TRAW?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis